← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Isabelle Ducellier
Styrelseledamot
Profile key: se|isabelle ducellier
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 0
- Purchases · 24M
- 5
- Average purchase
- SEK 33,146
- Gross purchase value
- SEK 165,732
- Last purchase
- 2025-06-12
- Completed 20D events
- 5.0
- Outcome status
- PASS
Latest company: Moberg Pharma AB (publ)
Companies: Devyser Diagnostics AB | Lyko Group AB (publ) | Moberg Pharma AB (publ)
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing | 100.0% (5/5) | 60.0% (3/5) | +2.9% | +0.6% | -7.0% |
| 20D | 5Developing | 100.0% (5/5) | 40.0% (2/5) | -0.1% | +4.6% | -1.0% |
| 60D | 5Developing | 100.0% (5/5) | 80.0% (4/5) | +12.1% | +11.7% | -17.6% |
| 120D | 5Developing | 100.0% (5/5) | 40.0% (2/5) | -4.2% | -4.9% | -15.7% |
Research patterns
- First purchase in 12M
- 0/2
- Large purchase ≥ €100k
- 0/5
- Cluster buying · 15D
- 0/5
- Buying the dip · ≥20% below prior 52W high
- 5/5
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.